ASSOCIATION OF MTHFR A1298C POLYMORPHISM WITH BREAST CANCER AND/OR OVARIAN CANCER RISK: AN UPDATED META ANALYSIS
BACKGROUND Recent years have witnessed the discovery of similar gene variations between breast cancer and ovarian cancer, inherited breast and ovarian cancer in particular. A large number of case control studies have been conducted to explore the association of Methylenetetrahydrofolate Reductase (MTHFR) A1298C polymorphism with breast cancer and/or ovarian cancer risk. However, the results are still inconsistent and inconclusive. Consequently, we performed a meta analysis to evaluate the association between MTHFR A1298C polymorphism and breast, ovarian cancer risk. MATERIALS AND METHODS A comprehensive retrieval was conducted in the electronic database of PubMed, Web of Science and Chinese National Knowledge Infrastructure (CNKI) until June 2015 to identify eligible studies. A total of 35 studies which examined the association of MTHFR A1298C polymorphism with breast cancer and/or ovarian cancer were identified. The pooled odds ratios (ORs) with 95 confidence intervals (CIs) were used to assess the effect of gene polymorphism. And allele model, homozygous model, co dominant model, dominant model, recessive model were applied. RESULT In the overall analysis, significantly increased breast cancer and/or ovarian cancer risk was found (for allele model A VS C OR 1.05, CI: 1.02 1.08, P 4kh10 3; for homozygous model AA VS CC OR 1.11, CI: 1.03 1.19, P 5kh10 3; for recessive model (AC +AA) VS CC: OR 1.10, CI: 1.03 1.18, P 7kh10 3) CONCLUSION In the subgroup analysis, significantly increased breast cancer risk was identified among Caucasians. MTHFR A1298C polymorphism might contribute to an increased risk of breast cancer and/or ovarian cancer susceptibility. In addition, MTHFR A1298C polymorphism had a significant association with breast cancer in Caucasians.
African journal of traditional, complementary, and alternative medicines AJTCAM